Lipid nanoparticles for delivering therapeutic payloads to t cells
By designing lipid nanoparticles (LNPs) containing ionizable lipids and targeting components, the problems of low delivery efficiency and high toxicity of lipid nanoparticles when delivered to immune cells were solved, enabling efficient and safe delivery of therapeutic agents and gene editing to T cells.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- TESSERA THERAPEUTICS INC
- Filing Date
- 2024-10-22
- Publication Date
- 2026-07-21
AI Technical Summary
Existing lipid nanoparticles (LNPs) face challenges in delivering therapeutic payloads to immune cells such as T cells, including low delivery efficiency, high toxicity, and difficulty in bypassing in vivo barriers, particularly liver uptake and phagocytic uptake, leading to inaccurate therapeutic distribution and potential toxicity.
Lipid nanoparticles (LNPs) containing ionizable lipids and targeting moieties, such as V003, have been developed to encapsulate therapeutic agents and improve T-cell delivery efficiency through specific targeting moieties, reduce hepatic uptake and toxicity, and improve pharmacokinetics and endosomal release by using polyethylene glycol-modified lipids.
It significantly improves the delivery efficiency of therapeutic payloads to T cells, reduces hepatic uptake and toxicity, and achieves efficient and safe gene modification and therapeutic effects, such as the effective expression of gene editing systems in the treatment of cancer and autoimmune diseases.
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3